Abivax Initiates Public Offering of American Depositary Shares

On June 30, 2026, Abivax SA, a biotechnology company, announced the launch of a public offering of approximately $600 million in American Depositary Shares (ADSs) in the United States. Each ADS represents one ordinary share of Abivax. The offering will be executed under an underwriting agreement with the price and size determined through a book-building process.

Abivax's ADSs are already listed on Nasdaq, and the company plans to use the proceeds for potential commercialization of its drug obefazimod, and research on inflammatory diseases like Crohn’s disease and ulcerative colitis. The offering's completion remains contingent on market conditions and other factors.

Board members and executives are subject to a 60-day lock-up period, preventing the sale of shares during this timeframe. The offering involves significant risks, including potential dilution of share value and market price depression due to additional sales of shares.